Bolt Biotherapeutics Inc (BOLT)

$0.50 +0.00 (0.90%)
Market Cap 18.95M
Revenue (ttm) 7.88M
Net Income (ttm) -69.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -878.17%
Debt to Equity Ratio 0.00
Volume 205,700
Avg Vol 175,794
Day's Range N/A - N/A
Shares Out 38.27M
Stochastic %K 9%
Beta 0.96
Analysts Hold
Price Target $1.75

Latest News on BOLT

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 3 months ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 5 months ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 5 months ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 4, 2024, 11:00 AM EDT - 5 months ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 2, 2024, 11:11 AM EDT - 5 months ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Sep 2, 2024, 11:00 AM EDT - 5 months ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 31, 2024, 11:25 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 31, 2024, 11:00 AM EDT - 5 months ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

The Schall Law Firm Is Looking For Investors With Losses In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Case

Aug 30, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Is Looking For Investors With Losses In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Case

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 29, 2024, 8:49 PM EDT - 5 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bolt Biotherapeutics Inc. Is Being Sued For Securities Law Violations And Stockholders Are Invited To Contact The Schall Law Firm

Aug 29, 2024, 11:00 AM EDT - 5 months ago

Bolt Biotherapeutics Inc. Is Being Sued For Securities Law Violations And Stockholders Are Invited To Contact The Schall Law Firm

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 28, 2024, 8:35 PM EDT - 5 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

Aug 28, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Aug 27, 2024, 11:00 AM EDT - 5 months ago

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

A Case Is Being Pursued Against Bolt Biotherapeutics Inc For Securities Law Violations And The Schall Law Firm Urges Investors To Take Part

Aug 25, 2024, 11:00 AM EDT - 5 months ago

A Case Is Being Pursued Against Bolt Biotherapeutics Inc For Securities Law Violations And The Schall Law Firm Urges Investors To Take Part

The Schall Law Firm Is Suing Bolt Biotherapeutics, Inc. For Securities Law Violations And Stakeholders Are Urged To Join

Aug 23, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Is Suing Bolt Biotherapeutics, Inc. For Securities Law Violations And Stakeholders Are Urged To Join

Bolt Biotherapeutics, Inc. Investors Are Invited By The Schall Law Firm To Lead A Securities Fraud Case

Aug 22, 2024, 11:00 AM EDT - 5 months ago

Bolt Biotherapeutics, Inc. Investors Are Invited By The Schall Law Firm To Lead A Securities Fraud Case

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:05 PM EDT - 6 months ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

BOLT Investors Are Invited To Take The Lead In The Bolt Biotherapeutics Inc Securities Fraud Case With The Schall Law Firm

Aug 7, 2024, 9:15 PM EDT - 6 months ago

BOLT Investors Are Invited To Take The Lead In The Bolt Biotherapeutics Inc Securities Fraud Case With The Schall Law Firm

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 26, 2024, 10:00 AM EDT - 6 months ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 6 months ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before September 3, 2024 to Discuss Your Rights - BOLT

Jul 23, 2024, 5:00 PM EDT - 6 months ago

Bolt Biotherapeutics, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before September 3, 2024 to Discuss Your Rights - BOLT

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Jul 19, 2024, 11:10 AM EDT - 6 months ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jul 3, 2024, 4:47 PM EDT - 7 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jun 24, 2024, 3:36 PM EDT - 7 months ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:37 PM EDT - 9 months ago

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 4:05 PM EDT - 11 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 27, 2024, 7:00 AM EST - 1 year ago

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Dec 5, 2023, 7:00 AM EST - 1 year ago

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Oct 23, 2023, 10:30 AM EDT - 1 year ago

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Oct 17, 2023, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

Sep 12, 2023, 8:05 AM EDT - 1 year ago

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042